This clinical trial is focused on studying a condition known as Light Chain (AL) Amyloidosis, which is a rare disease where abnormal proteins build up in organs and tissues, affecting their normal function. The study will evaluate the effectiveness and safety of a treatment involving a medication called Birtamimab, which is a type of protein designed to target and neutralize harmful substances in the body. Birtamimab will be used in combination with the standard treatment for AL amyloidosis, which includes medications like Bortezomib, a drug that helps to slow down or stop the growth of abnormal cells. The study will also involve a comparison with a placebo, which is an inactive substance used to assess the treatment’s true effects.

The purpose of the study is to determine how well Birtamimab, when added to the standard treatment, works in patients with a severe form of AL amyloidosis, known as Mayo Stage IV. Participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will be conducted in two phases: a double-blind phase, where neither the participants nor the researchers know who is receiving the actual treatment or the placebo, and an open-label extension phase, where all participants will receive Birtamimab to evaluate its long-term safety.

Throughout the study, researchers will monitor the participants’ health and track important outcomes, such as the time it takes for any cause of death to occur during the double-blind phase. Additionally, they will assess changes in physical abilities and quality of life over a period of nine months. This trial aims to provide valuable insights into the potential benefits of Birtamimab for patients with AL amyloidosis, offering hope for improved treatment options in the future.